---
title: "Apellis Pharmaceuticals, Inc. (APLS.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/APLS.US.md"
symbol: "APLS.US"
name: "Apellis Pharmaceuticals, Inc."
industry: "生物技术"
---

# Apellis Pharmaceuticals, Inc. (APLS.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [apellis.com](https://apellis.com) |

## Company Profile

Apellis Pharmaceuticals, Inc.是一家商业阶段的生物制药公司，专注于发现、开发和商业化新型治疗化合物，以治疗具有高度未满足需求的疾病。该公司提供 EMPAVELI 用于治疗阵发性夜间血红蛋白尿；以及 SYFOVRE 用于治疗与年龄相关的黄斑变性和地理性萎缩（GA）引起的地理性萎缩。该公司还开发 EMPAVELI 用于治疗 C3 肾小管病和免疫复合物膜增生性肾小球肾炎、造血干细胞移植相关的血栓性微血管病、局灶性节段性肾小管硬化和延迟移植物功能；以及 APL-3007，一种小干扰 RNA（siRNA），用于治疗 GA。该公司与瑞典孤儿生物制药公司（Swedish Orph...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:13.000Z

**Overall: B (0.26)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 25 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 42.11% |  |
| Net Profit YoY | 117.99% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 6.84 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 2.75B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 1.02B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.10% | B |
| Profit Margin | 4.43% | C |
| Gross Margin | 79.78% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 42.11% | A |
| Net Profit YoY | 117.99% | A |
| Total Assets YoY | 17.39% | A |
| Net Assets YoY | 69.18% | A |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 2259.36% | A |
| OCF YoY | 42.11% | A |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.04 | A |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 62.11% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Apellis Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.10%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "4.43%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "79.78%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "42.11%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "117.99%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "17.39%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "69.18%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "2259.36%",
          "rating": "A"
        },
        {
          "name": "OCF YoY",
          "value": "42.11%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.04",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "62.11%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯维 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 61.03 | 52/605 | 70.22 | 62.41 | 57.18 |
| PB | 6.84 | 342/605 | 18.74 | 13.49 | 7.50 |
| PS (TTM) | 2.70 | 62/605 | 4.07 | 3.13 | 2.81 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-02T05:00:00.000Z

Total Analysts: **22**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 11 | 50% |
| Overweight | 3 | 14% |
| Hold | 7 | 32% |
| Underweight | 0 | 0% |
| Sell | 1 | 5% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 21.70 |
| Highest Target | 55.00 |
| Lowest Target | 19.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/APLS.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/APLS.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/APLS.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.